Conventional Regimen to BPaL/M : Effectiveness and Predictors of Successful Drug-Resistant Tuberculosis Therapy in South Kalimantan
DOI:
https://doi.org/10.31351/vol35iss3pp129-137Keywords:
gender, predictor factor, comorbid DM, treatment success, resistant patternAbstract
This study aimed to analyze the comparative efficacy of conventional and BPaL/M regimens and identify predictors of treatment success in drug-resistant tuberculosis (DR-TB) patients receiving BPaL/M in South Kalimantan during the period 2022-2024. The study included 245 DR-TB patients. The Mann-Whitney test showed a significant difference in clinical outcome scores between patients receiving conventional treatment and BPaL/M treatment (P<0.001), and the group of patients receiving conventional treatment had a higher probability of treatment failure compared to the group receiving BPaL/M. Predictors of treatment success in BPaL/M regimens using logistic regression showed that sex (OR = 10.772; %CI: 1.051-110.416, P = 0.045) was significantly associated with TB treatment success, while comorbidities such as diabetes and resistant type were not. Efforts should be made to achieve successful treatment in male patients by increasing understanding and adherence to treatment through various efforts, for example, reminders to take medication
How to Cite
Publication Dates
Received
Revised
Accepted
Published Online First
References
Kemenkes RI. Profil Kesehatan Indonesia Tahun 2023. Kementerian Kesehatan Republik Indonesia; 2024.
World Health Organization (WHO). Global Tuberculosis Report 2023. World Health Organization; 2023.
Pusdatin KR. Infodatin : Tuberkulosis.; 2018. www.who.int/gho/mortality_burden_disease/cause_death/top10/en/
Kemenkes RI. Program Penanggulangan Tuberkulosis Tahun 2022.; 2023.
Lestari BW, Nijman G, Larasmanah A, et al. Management of drug-resistant tuberculosis in Indonesia: a four-year cascade of care analysis. The Lancet Regional Health - Southeast Asia. 2024;22. doi:10.1016/j.lansea.2023.100294
Silva DR, Fernandes FF, Ferreira JC, et al. Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review. Jornal Brasileiro de Pneumologia. 2025;50(6):e20240295. Doi : 10.36416 / 1806 -3756 /e20240295
Nailius IS, Anshari D. Hubungan Karakteristik Sosial Demografi dan Literasi Kesehatan Dengan Kepatuhan Minum Obat Pada Penderita Tuberkulosis di Kota Kupang. Perilaku dan Promosi Kesehatan: Indonesian Journal of Health Promotion and Behavior. 2022;4(2):43. doi:10.47034/ppk.v4i2.6332
Azwar GA, Indah Noviana D, Hendriyono FX. Karakteristik Penderita Tuberkulosis Paru Dengan Multidrug-Resistant Tuberculosis (Mdr-Tb) Di Rsud Ulin Banjarmasin. Berkala Kedokteran. 2017;13(1):23-32.
Kusumaningrum D, Mertaniasih NM, Soedarsono S. The performance of A rpob gene mutation linked to A resistant to rifampicin mycobacterium tuberculosis isolate from an Indonesian referral hospital. Indian Journal of Tuberculosis. Published online 2024.doi: https://doi.org/10.1016/j.ijtb.2024.06.013
Long Q, Qu Y, Lucas H. Drug-resistant tuberculosis control in China: Progress and challenges. Infectious Disease of Poverty. 2016;5(1). doi:10.1186/s40249-016-0103-3.
Duan Q, Chen Z, Chen C, et al. The prevalence of drug-resistant tuberculosis in mainland China: An updated systematic review and meta-analysis. PLoS One. 2016;11(2). doi:10.1371/journal.pone.0148041
Borrell S, Gagneux S. Strain diversity, epistasis and the evolution of drug resistance in Mycobacterium tuberculosis. Clinical Microbiology and Infection. 2011;17(6):815-820. doi:10.1111/j.1469-0691.2011.03556.x
Karuniawati H, Putra ON, Wikantyasning ER. Impact of pharmacist counseling and leaflet on the adherence of pulmonary tuberculosis patients in lungs hospital in Indonesia. Indian Journal of Tuberculosis. 2019;66(3):364-369. doi:https://doi.org/10.1016/j.ijtb.2019.02.015
Jin C, Wu Y, Chen J, et al. Prevalence and patterns of drug-resistant Mycobacterium tuberculosis in newly diagnosed patients in China: A systematic review and meta-analysis. Journal of Global Antimicrobial Resistant. 2024;38:292-301. doi:10.1016 /j.jgar .2024 .05. 018
Soedarsono S, Mertaniasih NM, Kusmiati T, Permatasari A, Ilahi WK, Anggraeni AT. Characteristics of Previous Tuberculosis Treatment History in Patients with Treatment Failure and the Impact on Acquired Drug-Resistant Tuberculosis. Antibiotics. 2023;12(3):1. doi:10.3390/antibiotics12030598
Wang J, Wang J, Du Y, et al. Effect of interval between food intake and drug administration at fasting condition on the plasma concentrations of first-line anti-tuberculosis drugs in Chinese population. Medicine (United States). 2020;99(44):1-5. doi:10. 1097 /MD .00000000 00022258
Kumar AKH, Chandrasekaran V, Kumar AK, et al. Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs. Indian Journal of Medical Research. 2017;145(April):530-535. doi:10. 4103/ ijmr. IJMR_552_15
Kumari DS, Gupta DA, Chopra DV, Kaur DS. Treatment outcomes of multidrug resistant tuberculosis (MDR TB) treated with bedaquiline under programmatic management of drug resistant tuberculosis at a tertiary care hospital in Punjab, India. Indian Journal of Tuberculosis. 2024;71:S67-S71. doi:https:// doi. org/10.1016/j.ijtb.2023.12.003
Kemenkes RI. Petunjuk Teknis Penatalaksanaan Tuberkulosis Resistan Obat Di Indonesia. Kementerian Kesehatan Republik Indonesia; 2020.
Van Rie A, Walker T, De Jong B, et al. Balancing access to BPaLM regimens and risk of resistance. The Lancet Infectious Disease. 2022;22:1411-1412. doi:10.1016/S1473-3099 ( 22) 00543-6ï
Putra ON, Purnamasari T. BPaL/BpaLM regimen: A bright future for drug-resistant tuberculosis. Asian Pacific Journal Tropical Medicine. 2024 ;17(8):335-337. doi: 10. 4103 /apjtm.apjtm_244_24
Kemenkes RI. Buku Pegangan Operasional : Pengobatan Tuberkulosis Resisten Obat Dengan Panduan BPaL/M. Kementerian Kesehatan Republik Indonesia; 2023.
Wiker HG. Tuberculosis: insights into latency, treatment strategies, and the potential roles of metronidazole. Frontiers in Tuberculosis. 2023;1. doi:10.3389/ftubr.2023.1230713
Johnson TM, Rivera CG, Lee G, Zeuli JD. Pharmacology of emerging drugs for the treatment of multi-drug resistant tuberculosis. Journal of Clinical Tuberculosis and Other Mycobacterial Disease. 2024;37. doi: 10. 1016 /j.jctube.2024.100470
Occhineri S, Matucci T, Rindi L, et al. Pretomanid for tuberculosis treatment: an update for clinical purposes. Current Research in Pharmacology and Drug Discovery. 2022;3:1. doi:10.1016/j.crphar.2022.100128
Conradie F, Bagdasaryan TR, Borisov S, et al. Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis. New England Journal of Medicine. 2022;387(9):810-823. doi: 10.1056/nejmoa2119430.
Downloads
Published
License
Copyright (c) 2026 Iraqi Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
